Serum levels of adiponectin differentiate generalized lipodystrophies from anorexia nervosa.
Anorexia nervosa
High molecular weight adiponectin
Leptin
Lipodystrophy
Progeroid lipodystrophies
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
15 Feb 2024
15 Feb 2024
Historique:
received:
07
12
2023
accepted:
09
01
2024
medline:
15
2
2024
pubmed:
15
2
2024
entrez:
15
2
2024
Statut:
aheadofprint
Résumé
The differential diagnosis of lipodystrophy involves other disorders characterized by severe fat loss and may be sometimes challenging. Owing to the rarity of lipodystrophy, it is relevant to search for tools and assays that differentiate it from other diseases that may mimic it. We conducted a study on leptin and high molecular weight (HMW) adiponectin serum concentrations in a series of patients diagnosed with lipodystrophy and compared them with those found in anorexia nervosa, one of the illnesses that may be cause of a missed diagnosis of lipodystrophy. Leptin and HMW adiponectin serum concentrations were measured in six patients diagnosed with generalized lipodystrophy (GL), six with progeroid syndromes (PS), 13 with familial partial lipodystrophy type 1 (FPLD1, Kobberling syndrome), 10 with familial partial lipodystrophy type 2 (FPLD2, Dunnigan syndrome), 18 with acquired partial lipodystrophy (APL) and 12 affected by anorexia nervosa (AN). Measurements were compared to those obtained in 12 normal weight healthy subjects. Serum leptin concentrations were reduced to a similar degree in GL, PS and AN, proportionally to the extent of fat loss. Serum concentrations of HMW adiponectin were found extremely low in patients with GL and PS, while comparable to normal weight subjects in patients with AN. Serum HMW adiponectin can be regarded as a useful tool to discriminate between generalized lipodystrophy syndromes (including PS) and AN.
Identifiants
pubmed: 38358463
doi: 10.1007/s40618-024-02308-3
pii: 10.1007/s40618-024-02308-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero dell'Università e della Ricerca
ID : PRIN 2020NCKXBR
Informations de copyright
© 2024. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).
Références
Araujo-Vilar D, Santini F (2019) Diagnosis and treatment of lipodystrophy: a step-by-step approach. J Endocrinol Invest 42(1):61–67
doi: 10.1007/s40618-018-0887-z
pubmed: 29704234
Garg A (2011) Clinical review: lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab 96(11):3313–3325
doi: 10.1210/jc.2011-1159
pubmed: 21865368
pmcid: 7673254
Brown RJ, Araujo-Vilar D, Cheung PT et al (2016) The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab 101(12):4500–4511
doi: 10.1210/jc.2016-2466
pubmed: 27710244
pmcid: 5155679
Handelsman Y, Oral EA, Bloomgarden ZT et al (2013) The clinical approach to the detection of lipodystrophy—an AACE consensus statement. Endocr Pract 19(1):107–116
doi: 10.4158/endp.19.1.v767575m65p5mr06
pubmed: 23435042
pmcid: 4108221
Foss-Freitas MC, Akinci B, Luo Y et al (2020) Diagnostic strategies and clinical management of lipodystrophy. Expert Rev Endocrinol Metab 15(2):95–114
doi: 10.1080/17446651.2020.1735360
pubmed: 32368944
Ceccarini G, Magno S, Gilio D et al (2021) Autoimmunity in lipodystrophy syndromes. Presse Med 50(3):104073. https://doi.org/10.1016/j.lpm.2021.104073
doi: 10.1016/j.lpm.2021.104073
pubmed: 34547374
Zhang Y, Proenca R, Maffei M et al (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432. https://doi.org/10.1038/372425a0
doi: 10.1038/372425a0
pubmed: 7984236
Scherer PE, Williams S, Fogliano M et al (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746–26749
doi: 10.1074/jbc.270.45.26746
pubmed: 7592907
Haque WA, Shimomura I, Matsuzawa Y et al (2002) Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 87(5):2395. https://doi.org/10.1210/jcem.87.5.8624
doi: 10.1210/jcem.87.5.8624
pubmed: 11994394
Lindvall Dahlgren C, Wisting L, Rø ØJ (2017) Feeding and eating disorders in the DSM-5 era: a systematic review of prevalence rates in non-clinical male and female samples. Eat Disord 28(5):56. https://doi.org/10.1186/s40337-017-0186-7
doi: 10.1186/s40337-017-0186-7
Araújo-Vilar D, Fernández-Pombo A, Cobelo-Gómez S et al (2022) Lipodystrophy-associated progeroid syndromes. Hormones (Athens) 21(4):555–571. https://doi.org/10.1007/s42000-022-00386-7
doi: 10.1007/s42000-022-00386-7
pubmed: 35835948
Magno S, Ceccarini G, Pelosini C et al (2020) Atypical progeroid syndrome and partial lipodystrophy due to LMNA gene p.R349W mutation. J Endocr Soc 4(10):bvaa108. https://doi.org/10.1210/jendso/bvaa108
doi: 10.1210/jendso/bvaa108
pubmed: 32913962
pmcid: 7474543
Ceccarini G, Gilio D, Magno S et al (2022) Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p. R349W mutation. J Endocrinol Invest 6:1–7. https://doi.org/10.1007/s40618-022-01795-6
doi: 10.1007/s40618-022-01795-6
Chen L, Lee L, Kudlow BA et al (2003) LMNA mutations in atypical Werner’s syndrome. Lancet 362(9382):440–445. https://doi.org/10.1016/S0140-6736(03)14069-X
doi: 10.1016/S0140-6736(03)14069-X
pubmed: 12927431
Pelosini C, Martinelli S, Ceccarini G et al (2014) Identification of a novel mutation in the polymerase delta 1 (POLD1) gene in a lipodystrophic patient affected by mandibular hypoplasia, deafness, progeroid features (MDPL) syndrome. Metabolism 63(11):1385–1389. https://doi.org/10.1016/j.metabol.2014.07.010
doi: 10.1016/j.metabol.2014.07.010
pubmed: 25131834
Garg A, Sankella S, Xing C et al (2016) Whole-exome sequencing identifies ADRA2A mutation in atypical familial partial lipodystrophy. JCI Insight 1(9):e86870. https://doi.org/10.1172/jci.insight.86870
doi: 10.1172/jci.insight.86870
pubmed: 27376152
pmcid: 4927009
Guillín-Amarelle C, Sánchez-Iglesias S, Castro-Pais A et al (2016) (2016) Type 1 familial partial lipodystrophy: understanding the Köbberling syndrome. Endocrine 54(2):411–421. https://doi.org/10.1007/s12020-016-1002-x
doi: 10.1007/s12020-016-1002-x
pubmed: 27473102
Magno S, Ceccarini G, Barison A et al (2021) Partial lipodystrophy and LMNA pR545H variant. J Clin Med 10(5):1142. https://doi.org/10.3390/jcm10051142
doi: 10.3390/jcm10051142
pubmed: 33803191
pmcid: 7963176
Magno S, Ceccarini G, Corvillo F et al (2023) Clinical characteristics of patients with acquired partial lipodystrophy: a multicenter retrospective study. Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgad700
doi: 10.1210/clinem/dgad700
Tews D, Schulz A, Denzer C et al (2021) Lipodystrophy as a late effect after stem cell transplantation. J Clin Med 10(8):1559. https://doi.org/10.3390/jcm10081559
doi: 10.3390/jcm10081559
pubmed: 33917653
pmcid: 8068033
Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395(6704):763–770. https://doi.org/10.1038/27376
doi: 10.1038/27376
pubmed: 9796811
Maffei M, Halaas J, Ravussin E et al (1995) Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1:1155–1161. https://doi.org/10.1038/nm1195-1155
doi: 10.1038/nm1195-1155
pubmed: 7584987
Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26:439–451
doi: 10.1210/er.2005-0005
pubmed: 15897298
Hirose H, Yamamoto Y, Seino-Yoshihara Y et al (2010) Serum highmolecular-weight adiponectin as a marker for the evaluation and care of subjects with metabolic syndrome and related disorders. J Atheroscler Thromb 17:1201–1211
doi: 10.5551/jat.6106
pubmed: 20948162
Tagami T, Satoh N, Usui T et al (2004) Adiponectin in anorexia and bulimia nervosa. J Clin Endocrinol Metab 89(4):1833–1837. https://doi.org/10.1210/jc.2003-031260
doi: 10.1210/jc.2003-031260
pubmed: 15070952
Iwahashi H, Funahashi T, Kurokawa N et al (2003) Plasma adiponectin levels in women with anorexia nervosa. Horm Metab Res 35:537–540
doi: 10.1055/s-2003-42655
pubmed: 14517770
Delporte ML, Brichard SM, Hermans MP et al (2003) Hyperadiponectinaemia in anorexia nervosa. Clin Endocrinol (Oxf) 58:22–29
doi: 10.1046/j.1365-2265.2003.01702.x
pubmed: 12519408
Pannacciulli N, Vettor R, Milan G et al (2003) Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. J Clin Endocrinol Metab 88:1748–1752
doi: 10.1210/jc.2002-021215
pubmed: 12679468
Housova J, Anderlova K, Krizová J et al (2005) Serum adiponectin and resistin concentrations in patients with restrictive and binge/purge form of anorexia nervosa and bulimia nervosa. J Clin Endocrinol Metab 90(3):1366–1370. https://doi.org/10.1210/jc.2004-1364
doi: 10.1210/jc.2004-1364
pubmed: 15598689
Karageorgiou V, Furukawa TA, Tsigkaropoulou E et al (2020) Adipokines in anorexia nervosa: a systematic review and meta-analysis. Psychoneuroendocrinology 112:104485. https://doi.org/10.1016/j.psyneuen.2019.104485
doi: 10.1016/j.psyneuen.2019.104485
pubmed: 31805456
Cawthorn WP, Scheller EL, Learman BS et al (2014) Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction. Cell Metab 20(2):368–375. https://doi.org/10.1016/j.cmet.2014.06.003
doi: 10.1016/j.cmet.2014.06.003
pubmed: 24998914
pmcid: 4126847
Amitani H, Asakawa A, Ogiso K et al (2013) The role of adiponectin multimers in anorexia nervosa. Nutrition 29(1):203–206. https://doi.org/10.1016/j.nut.2012.07.011
doi: 10.1016/j.nut.2012.07.011
pubmed: 23237649
Antuna-Puente B, Boutet E, Vigouroux C et al (2010) Higher adiponectin levels in patients with Berardinelli-Seip congenital lipodystrophy due to seipin as compared with 1-acylglycerol-3-phosphate-o-acyltransferase-2 deficiency. J Clin Endocrinol Metab. 95(3):1463–1468. https://doi.org/10.1210/jc.2009-1824 . (PMID: 20097706)
doi: 10.1210/jc.2009-1824
pubmed: 20097706
Groeneveld MP, Huang-Doran I, Semple RK (2012) Adiponectin and leptin in human severe insulin resistance-diagnostic utility and biological insights. Biochimie. 94(10):2172–2179. https://doi.org/10.1016/j.biochi.2012.01.021 . (PMID: 22342226)
doi: 10.1016/j.biochi.2012.01.021
pubmed: 22342226